Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitomycin C + vindesine
- Development stage
- Unknown
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Mitomycin C + vindesine is a combination chemotherapy regimen consisting of two antineoplastic agents, mitomycin C and vindesine. Mitomycin C is an alkylating agent that acts as an antitumor antibiotic by cross-linking DNA strands, thereby inhibiting DNA synthesis and leading to cell death. Vindesine is a vinca alkaloid that inhibits microtubule formation in the mitotic spindle, preventing cell division during metaphase. This combination has been studied for use in advanced cancers such as breast cancer and non-small-cell lung cancer (NSCLC), often as part of multi-drug regimens or in patients with refractory disease[2][3]. The primary mechanism of action involves disruption of DNA replication (mitomycin C) and inhibition of microtubule assembly (vindesine), resulting in cytotoxic effects on rapidly dividing tumor cells.
- Other names
- mitomycin C and vindesinemitomycin plus vindesine
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on mitomycin C + vindesine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitomycin C + vindesine.